PerkinElmer will provide biochemical and genetic testing to support BioMarin's testing program aimed at Batten disease and mucopolysaccharidosis disorders.
The company is providing DNA/RNA extraction kits, viral RNA isolation platforms, workstations, and kits for detecting nucleic acids from the coronavirus to the lab.
Reuters reports federal investigators are looking into PerkinElmer's role in an alleged Medicare fraud, though the firm says it is unaware of any investigation.
Seegene said Monday that the Health Canada approval will enable hospitals and licensed labs there to run the assay immediately for high-volume testing.
A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.
